do not combine dpp-4 inhibitors with glp-1 receptor agonists guidance Frontiers do not combine dpp-4 inhibitors

In the pancreas, GLP-1RAs enhance insulin secretion and inhibit the release of glucagon, a hormone that induces the breakdown of stored sugars into the bloodstream

The clinical data suggesting a possible association come from post-marketing surveillance data that have substantial risk for bias and do not control for important confounding variables

obesity vs

Accordingly, better control of cardiovascular risk factors such as blood pressure (BP) in patients with T2D is required to achieve favorable cardiovascular safety goals

Sure enough, exendin-4 displayed all the same effects as GLP-1, triggering insulin secretion from the pancreas and slowing digestion

Increased signaling through exchange proteins directly activated by cAMP (EPACs), specifically EPAC2, and activation of protein kinase A (PKA) follow the rise in cAMP